Insights Into Renal Cell Carcinoma (RCC) 2025

Perspectives on drivers in treatment decisions in the management of RCC

Southeast – March 22, 2025
Purchase Report

Faculty Chair

Jacqueline Brown, MD

Winship Cancer Institute, Atlanta, GA, USA

Texas – June 23, 2025
Purchase Report

Faculty Chair

Andrew Hahn, MD

MD Anderson Cancer Center, Houston, TX, USA

More Information

  • Atlanta, GA
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual series
  • Texas

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of RCC
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.